


**Catalog # 10-2491**

**CUDC-101**

CAS# 1012054-59-9

7-((4-((3-Ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide

Lot # X105304



A novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,  $IC_{50}$  = 4.4, 2.4 and 15.7 nM respectively.<sup>1</sup> It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.<sup>1,2</sup>

- 1) Lai *et al.* (2010), *CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity*; *Cancer Res.*, **70** 3647
- 2) Cai *et al.* (2010), *Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer*; *J. Med. Chem.*, **53** 2000

**PHYSICAL DATA**

Molecular Weight:	434.49
Molecular Formula:	C <sub>24</sub> H <sub>26</sub> N <sub>4</sub> O <sub>4</sub>
Purity:	99% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 25 mg/ml)
Physical Description:	White or off-white solid
Storage and Stability:	Store as supplied, desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

**Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.**